TWiV 908: COVID-19 clinical update #118 with Dr. Daniel Griffin

In COVID-19 clinical update #118, Dr. Griffin discusses management of hair loss after infection, FDA announcements on vaccine schedule and recommendations, Moderna announcement on bivalent booster candidate, association between vaccination and infection during pregnancy, population-level implications of Israel’s booster campaign, PAXLOVID outcomes during recent infection surge, efficacy and safety of Tixagevimab-cilgavimab, diagnostic accuracy of infection by canines, efficacy of colchicine in hospitalized patients, and factors associated with hospital readmission.   Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email Become a patron of TWiV! Links for this episode Management of hair loss after infection (NIH) FDA announces vaccine schedule meeting (FDA) FDA advisory committee recommends NOVAVAX vaccine (Novavax) Moderna announces bivalent booster candidate (Moderna) Association of vaccination and infection during pregnancy (JAMA) Implications of Israeli booster campaign (Science Translational Medicine) PAXLOVID patient eligibility screening checklist (FDA) Remdesivir fact sheet for providers (Veklury)  Bebtelovimab fact sheet for providers (FDA) PAXLOVID outcomes during infection surge (Research Square) Efficacy and safety of Tixagevimab–cilgavimab (The Lancet) Diagnostic accuracy of infection by canines (PLOS ONE) Efficacy of colchicine in hospitalized patients (Nature) Factors associated with readmission (IDSA)  Contribute to FIMRC fundraiser at PWB Dr. Griffin’s treatment guide (pdf) Letters read on TWiV 908 Timestamps by Jolene. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to [email protected]